Table 2 Correlation between lymph node metastasis and clinicopathological features in cT1 breast cancer patients undergoing surgery
From: Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer
Parameters | All intrinsic subtype (n = 332) | HR + HER2-BC (n = 265) | HR + HER2 + BC (n = 11) | HER2enriched BC (n = 15) | TNBC (n = 41) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
pN0 or 1mic (n = 273) | pN1a or 2 (n = 59) | p value | pN0 or 1mic (n = 217) | pN1a or 2 (n = 48) | p value | pN0 (n = 9) | pN1a or 2 (n = 2) | p value | pN0 (n = 11) | pN1a or 2 (n = 4) | p value | pN0 (n = 36) | pN1a or 2 (n = 5) | p value | |
Age (years old) | |||||||||||||||
  ≤ 60 | 158 (57.9%) | 28 (47.5%) | 0.144 | 130.(59.9%) | 23.(47.9%) | 0.128 | 5 (55.6%) | 1 (50.0%) | 0.887 | 7(63.6%) | 3 (75.0%) | 0.680 | 16 (44.4) | 1 (20.0%) | 0.299 |
  > 60 | 115 (42.1%) | 31 (52.5%) | 87 (40.1%) | 25 (52.1%) | 4 (44.4%) | 1 (50.0%) | 4 (36.4%) | 1 (25.0%) | 20 (55.6%) | 4 (80.0%) | |||||
Tumor size (mm) | |||||||||||||||
  ≤ 10.0 | 54 (19.8%) | 4 (6.8%) | 0.016 | 45 (20.7%) | 4 (8.3%) | 0.045 | 2 (22.2%) | 0 (0.0%) | 0.461 | 0 (0.0%) | 0 (0.0%) |  | 7 (19.4%) | 0 (0.0%) | 0.279 |
  > 10.0 | 219 (80.2%) | 55 (93.2%) | 172 (79.8%) | 44 (91.7%) | 7 (77.8%) | 2 (100.0%) | 11 (100.0%) | 4 (100.0%) | 1.000 | 29 (80.6%) | 5 (100.0%) | ||||
Estrogen receptor | |||||||||||||||
 Negative | 50 (18.3%) | 9 (15.3%) | 0.577 | 3 (1.4%) | 0 (0.0%) | 0.413 | 0 (0.0%) | 0 (0.0%) | 1.000 | – | – |  | – | – | – |
 Positive | 223 (81.7%) | 50 (84.7%) | 214 (98.6%) | 48 (100.0%) | 9 (100.0%) | 2 (100.0%) | – | – | – | – | – | ||||
Progesterone receptor | |||||||||||||||
 Negative | 109 (39.9%) | 21 (35.6%) | 0.538 | 58 (26.7%) | 11 (22.9%) | 0.586 | 4 (44.4%) | 1 (50.0%) | 0.887 | – | – | – | – | – | – |
 Positive | 164 (60.1%) | 38 (64.4%) | 159 (73.3%) | 37 (77.1%) | 5 (55.6%) | 1 (50.0%) | – | – | – | – | |||||
Hormone receptor | |||||||||||||||
 Negative | 47 (17.2%) | 9 (15.3%) | 0.715 | – | – | – | – | – | – | – | – | – | – | – | – |
 Positive | 226 (82.8%) | 50 (84.7%) | – | – | – | – | – | – | – | – | |||||
HER2 | |||||||||||||||
 Negative | 253 (92.7%) | 53 (89.8%) | 0.461 | – | – | – | – | – | – | – | – | – | – | – | – |
 Positive | 20 (7.3%) | 6 (10.2%) | – | – | – | – | – | – | – | – | |||||
Ki67 | |||||||||||||||
  ≤ 14% | 166 (60.8%) | 40 (67.8%) | 0.316 | 148 (68.2%) | 37 (77.1%) | 0.225 | 3 (33.3%) | 0 (0.0%) | 0.338 | 1 (9.1%) | 0 (0.0%) | 0.533 | 22 (61.1%) | 3 (60.0%) | 0.962 |
  > 14% | 107 (39.2%) | 19 (32.2%) | 69 (31.8%) | 11 (22.9%) | 6 (66.7%) | 2 (100.0%) | 10 (90.9%) | 4 (100.0%) | 14 (38.9%) | 2 (40.0%) | |||||
Lymphatic invasion | |||||||||||||||
 ly0 | 201 (73.6%) | 28 (47.5%) | < 0.001 | 158 (72.8%) | 25 (52.1%) | 0.005 | 7 (77.8%) | 1 (50.0%) | 0.425 | 8 (72.7%) | 0 (0.0%) | 0.013 | 28 (77.8%) | 2 (40.0%) | 0.074 |
 ly1 | 72 (26.4%) | 31 (52.5%) | 59 (27.2%) | 23 (47.9%) | 2 (22.2%) | 1 (50.0%) | 3 (27.3%) | 4 (100.0%) | 8 (22.2%) | 3 (60.0%) | |||||
Venous invasion | |||||||||||||||
 v0 | 264 (96.7%) | 54 (91.5%) | 0.073 | 209 (96.3%) | 43 (89.6%) | 0.051 | 9 (100.0%) | 2 (100.0%) | 1.000 | 10 (90.9%) | 4 (100.0%) | 0.533 | 36 (100.0%) | 5 (100.0%) | 1.000 |
 v1 | 9 (3.3%) | 5 (8.5%) | 8 (3.7%) | 5 (10.4%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||||
Nuclear grade | |||||||||||||||
 1, 2 | 243 (89.0%) | 50 (84.7%) | 0.356 | 203 (93.5%) | 42 (87.5%) | 0.151 | 9 (100.0%) | 2 (100.0%) | 1.000 | 7 (63.6%) | 1 (25.0%) | 0.185 | 24 (66.7%) | 5 (100.0%) | 0.125 |
 3 | 30 (11.0%) | 9 (15.3%) | 14 (6.5%) | 6 (12.5%) | 0 (0.0%) | 0 (0.0%) | 4 (36.4%) | 3 (75.0%) | 12 (33.3%) | 0 (0.0%) | |||||
TILs (score) | |||||||||||||||
 0, 1 | 219 (80.2%) | 53 (89.8%) | 0..082 | 190 (87.6%) | 44 (91.7%) | 0.423 | 7 (77.8%) | 2 (100.0%) | 0.461 | 5 (45.5%) | 3 (75.0%) | 0.310 | 17 (47.2%) | 4 (80.0%) | 0.169 |
 2, 3 | 54 (19.8%) | 6 (10.2%) | 27 (12.4%) | 4 (8.3%) | 2 (22.2%) | 0 (0.0%) | 6 (54.5%) | 1 (25.0%) | 19 (52.8%) | 1 (20.0%) | |||||
TILs (score) | |||||||||||||||
 0 | 12 (4.4%) | 17 (28.8%) | < 0.001 | 11 (5.1%) | 14 (29.2%) | < 0.001 | 0 (0.0%) | 0 (0.0%) | 1.000 | 0 (0.0%) | 1 (25.0%) | 0.086 | 1 (2.8%) | 2 (40.0%) | 0.003 |
 1–3 | 261 (95.6%) | 42 (71.2%) | 206 (94.9%) | 34 (70.8%) | 9 (100.0%) | 2 (100.0%) | 11 (100.0%) | 3 (75.0%) | 35 (97.2%) | 3 (60.0%) | |||||